Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS. by Kyohere, Mary et al.
STUDY PROTOCOL
   Seroepidemiology of maternally-derived antibody 
against Group B Streptococcus (GBS) in Mulago/Kawempe 
Hospitals Uganda - PROGRESS GBS [version 2; peer review: 2 
approved]
Mary Kyohere1, Hannah Georgia Davies2, Philippa Musoke1,3, Annettee Nakimuli4, 
Valerie Tusubira 1, Hannington Baluku Tasimwa5, Juliet Sendagala Nsimire 6, 
Paul Heath2, Stephen Cose 7, Carol Baker8, Kirsty Le Doare 2,7*, 
Musa Sekikubo 4*
1Makerere University - Johns Hopkins University (MUJHU) Research Collaboration, Kampala, Uganda 
2Paediatric Infection and Immunology Institute of Infection and Immunity, St George’s, University of London, London, SW170RE, UK 
3Department of Paediatrics and Child Health, Makerere University, College of Health Sciences, Kampala, 256, Uganda 
4Department of Obstetrics and Gynaecology,, Makerere University, College of Health Sciences, Kampala, 256, Uganda 
5Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, 256, Uganda 
6Clinical Diagnostics Laboratories, MRC/UVRI/LSHTM, Entebbe, Uganda 
7Immunology and Vaccines Research Unit, MRC/UVRI and LSHTM Uganda, Entebbe, Uganda 
8University of Texas Health Science Center, McGovern Medical School, Houston, Texas, TX 77030, USA 
* Equal contributors
First published: 08 Oct 2020, 4:155  
https://doi.org/10.12688/gatesopenres.13183.1





Background: Group B Streptococcus (GBS) is a major contributor to 
the high burden of neonatal and young infant infectious disease in 
resource- limited settings. As disease protection during the first six 
months of life is provided via placental transfer of maternal 
antibodies, a maternal GBS vaccine may provide an effective strategy 
to reduce infectious death and disability. An efficacy study may be 
difficult because of the large sample size required and alternative 
approaches such as serocorrelates of protection based on natural 
antibody concentration are being considered. Such studies would 
need to be undertaken in high burden settings such as Uganda. We 
therefore aim to evaluate the feasibility and acceptability of a GBS 
sero-epidemiology study in Kampala, Uganda. 
Methods: This is a prospective cohort and nested case-control study, 
conducted across two-centres with two entry points. A) consecutive 
women and their infants at birth, with collection of maternal swab, 
cord and maternal blood, and follow up by telephone until the infant 
is 3 months old; B) any infant under 3 months of age, presenting with 
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signs of sepsis to any of the paediatric units, with collection of blood 
culture, cerebrospinal fluid and nasopharyngeal swabs. Any infants 
identified as having GBS disease (defined as GBS isolated from a 
normally sterile site) will be recruited and followed up for two years to 
assess their neurodevelopment. A nested qualitative study will 
investigate stakeholder (pregnant women and their families, 
healthcare workers and community leaders) opinions of sampling for 
such a study and understanding and potential uptake of vaccines in 
pregnancy. 
Discussion: The primary aim is to determine anti-GBS antibody 
concentration in infants with GBS disease compared to healthy 
controls. Secondary outcomes include stillbirth and all-cause infection 
and acceptance of sample methods and vaccination. The findings will 
inform scalability and sustainability of the programme in Uganda.
Keywords 
Group B Streptococcus, antibody, neonatal sepsis, Uganda, neonate, 
infant, sero-epidemiology, vaccine
Any reports and responses or comments on the 
article can be found at the end of the article.
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Introduction
The last ten years have seen major improvements in the 
number of deaths in children less than five years of age in 
many regions of Africa. However, the unacceptably high death 
rates amongst newborns have not declined at the same rate. 
Approximately one-third of these deaths are due to severe infec-
tion. Group B Streptococcus (GBS) meningitis and severe 
bloodstream infection are likely to be major contributors to this 
very high disease burden in Africa and other resource-limited 
settings. Globally, GBS colonization is estimated to be present 
in 21.7 million pregnant women. A 2015 estimate showed more 
than 319,000 infants <3 months of age with invasive GBS disease 
(iGBS), 90,000 infant deaths and more than 10,000 children 
with GBS meningitis related disability1. 33,000 maternal deaths 
and 57,000 stillbirths were also ascribed to GBS disease1.
Intrapartum antibiotic prophylaxis (IAP) can reduce the 
incidence of early onset disease (EOD) but has no impact on 
late onset disease (LOD) and only a limited impact on disease in 
pregnant women2. In settings such as Uganda, IAP implementation 
is likely to be poor because of irregular attendance at 
antenatal care. In the UK and USA, GBS is the commonest 
cause ofbacterial meningitis in children under 51, with most 
GBS meningitis occuring after week one of life, hence the 
burden persists.
Although GBS-colonization is common, very few colonized 
infants subsequently develop iGBS (1-2%). With regards to titers 
of naturally occurring serotype-specific maternal antibody to 
GBS-capsular polysaccharide (CPS), studies have shown a 
correlation between high titres and reduced risk of disease in 
neonates3. Baker and colleagues4 initially characterized the asso-
ciation between iGBS in newborns and serotype (ST)-specific 
CPS antibody levels in 1976. Infants with EOD and LOD were 
found to have lower ST-specific CPS antibodies than controls 
in most subsequent studies. There is now consensus that these 
data suggest that maternal immunization may be an effective 
strategy for protection5.
Results from a meta-analysis comparing the proportions of 
cases and controls with antibody levels ≥2 ug/ml for sero-
types III and Ia, showed iGBS was (OR=6.56 CI: 2.10–20.55) 
and (OR=2.38 CI: 1.20–4.70) times greater in infants whose 
mothers had antibody levels <2 ug/ml respectively6. 1 ug/ml 
has also recently been proposed as a threshold for correlate of 
protection against ST Ia and III3. Other larger studies, includ-
ing a study from South Africa7, where HIV prevalence is high, 
show much higher thresholds. Lack of available standardized 
reference sera and differences in methods make interpretation of 
these results difficult. A standardized approach to establish 
antibody concentration and function and its role in reduc-
ing neonatal disease is vital in achieving licensure of any 
future vaccines and is currently underway through funding 
from the Bill and Melinda Gates Foundation and collaborators 
involved in this proposal8.
The likelihood of protecting mothers and their infants through 
vaccination in pregnancy is made desirable by the early onset 
of neonatal GBS disease, the shortfalls of prevention strategies 
using IAP and evidence suggesting maternal antibodies transmit-
ted transplacentally may protect the young infant from invasive 
infection3
To be considered for an effective vaccine are the various 
conserved surface proteins or the CPS. The immunogenic-
ity and safety of CPS - protein conjugate vaccines have been 
demonstrated through several studies in non-pregnant and, 
more recently, in pregnant women9.
The most advanced vaccines face a number of obstacles in 
moving into phase III clinical trials. First, iGBS in Europe 
and the United States is relatively rare so determining effi-
cacy of a vaccine in settings such as these would require large 
numbers of infants to be recruited10. Second, there are obsta-
cles determining the concentration of antibody that is needed 
to protect the infant throughout the first three months of 
life since, at the moment there are no standards with which 
to interpret individual study results that are recognized 
internationally11. An immune marker, measured using a 
validated assay, and established as a correlate of protection 
would markedly accelerate policy and licensure decisions. A 
commitment for effectiveness post-licensure to be established 
would be made in this case, similar to the approach that was 
used for meningococcal C and meningococcal B vaccines 
licensure12.
Such serocorrelates of protection should be based within 
high burden settings, such as Uganda and analysed in women 
living with HIV, where antibody transfer may be impaired, 
compared to HIV-negative women. Thus, this study aims to 
evaluatethe feasibility and acceptability of undertaking a large 
sero-epidemiology study of GBS in two urban hospitals in 
Kampala, Uganda.
Methods
The PROGRESS Group B Streptococcus Study is a feasibility 
and nested case-control study of the first 6000 women to deliver 
at Kawempe Hospital and active surveillance for 12 months 
at Kawempe National Referral Hospital and Mulago National 
Referral Hospital for neonatal infection. 
Sample size calculation
Cases: Based on previous Correlate of Protection (CoP) studies3,7, 
feasible correlates are those that give 80-90% risk reduc-
tions. In a case-control study, an 80% reduction is equal 
to an Odds Ratio (OR) of 0.2. Table 1 shows the precision 
around 0.2 for varying case sample sizes and proportion of 
controls with IgG levels above the potential CoP levels (“cuts”).
          Amendments from Version 1
We have updated some typos and methods as suggested by the 
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70% 0�08-0�49 0�12-0�33 0�13-0�30
50% 0�07-0�57 0�11-0�37 0�13-0�32
30% 0�05-0�81 0�09-0�45 0�11-0�37
Therefore with 30 cases the 95% CI around an 80% reduction 
is 43% to 93%; and with 90 cases it is 63% to 89% if 50% of 
controls have levels above the cutoff.
The incidence of iGBS among infants < 3 months of age in 
Uganda is not known. A study from Mulago Hospital in 5 months 
during 2002 identified 7 cases of GBS disease in a cohort 
of 293 infants admitted with signs of sepsis (2% of all infec-
tion, 25% of positive cultures (2 EOD, 5 LOD))13. A more recent 
study from 2010 in Mbarara identified 80 infants with 
presumed infections over a 10 month period identified 1 case of 
early onset GBS infection (1% of infections, 50% of positive 
cultures)14. No serotype data is available from either study. 
These are likely underestimates due to manual culture methods 
used and recruits were only those infants who presented to the 
hospital with signs of infection and we know that in the first 
weeks of life many infants are born and die at home.
Based on the most recent analysis of cost-effectiveness for a 
potential GBS vaccine in Uganda, Guinea Bissau, Nigeria and 
Ghana, GBS disease incidence of 1.13/1000 livebirths was used 
to demonstrate the prospects of a multivalent vaccine against 
GBS to prevent approx. 1/3 of all GBS cases and deaths in 
Uganda15.
Following a cohort of 35000 women with an incidence of 
1.13/1000 livebirths therefore would be expected to yield 
40 cases (95% CI 33-46); with an incidence of 2/1000 we would 
expect 70 cases (95% CI 61-79) of iGBS per annum with a 
sufficient number of cases for at least one of the most frequent 
serotypes i.e. STIII and STIa.
Controls: Controls are infants who are exposed to the same 
ST / strain of GBS at delivery as the case - but who do not 
develop iGBS in the first 90 days of life. To account for the 
lower placental transfer associated with prematurity they should 
also be born at ≥ 34 weeks’ gestation16. Additionally, they should 
not be born via caesarean section or have received IAP, as these 
will reduce their chance of developing EOD, and they should not 
have received a blood transfusion in the last month, as this may 
artificially affect their anti-GBS IgG concentrations.
We propose recruiting such controls through a prospective 
pregnancy swab study in which a rectovaginal swab will be 
obtained together with maternal delivery and cord sera during 
this feasibility study. The sample size for this study would be 
based on the need for a ratio of at least 3:1 controls per case 
for the main serotypes (III and Ia). In South-Western Uganda 
28.8% of women are found to be GBS colonised17. There is no 
serotypes distribution data. However, it is likely that serotypes 
will be similar to those in South Africa (32.8% III, 39.2% Ia)18. 
Thus ~ 70 iGBS cases of ST III iGBS will require matching 
with 210 controls (women colonised with ST III) i.e. 210/0.328 
~ 640 carriers, which implies 640/0.288 = 2222 women to be 
swabbed in the pregnancy swab study (this feasibility study). 
We will double this number to account for caesarean section, 
premature birth and intrapartum antibiotic exposure.
Study setting
The study is based at two Ugandan sites: one maternity national 
referral hospital (Kawempe Hospital, Kampala) and one 
general national referral hospital (Mulago Hospital, Kampala). 
Kawempe Hospital is the largest national referral hospital for 
pregnancies in Kampala, Uganda’s capital city, taking high-risk 
pregnancies from across the surrounding areas and all deliver-
ies from the local community. There is a small neonatal unit 
admitting all infants weighing under 1000g as well as neonates 
with birth-related complications, sepsis or congenital anoma-
lies (approximately 11,000 admissions per year). There are 
approximately 25,000 births per year at Kawempe. Mulago 
National Referral Hospital is a large hospital in Kampala with 
an official bed capacity of 1790. The hospital’s children’s 
services include outpatients, acute admissions and an inpatient 
malnutrition unit, as well as a weekly paediatric neurology clinic. 
The latter offers investigation and management of neurological 
conditions and a clinic-based occupational therapy and 
physiotherapy service for children with cerebral palsy and 
other Neurodevelopmental Impairments (NDIs).
Types of participants, recruitment process and consent
The study has two entry points, women and their infants 
consenting at birth (birth cohort), and any infant with signs 
of infection presenting before they are 3 months old (active 
surveillance cohort).
For the Birth Cohort the study will be advertised via posters 
in antenatal clinic to assist with sensitisation and a film 
(available as extended data19) will be produced to provide 
information to caregivers regarding neonatal sepsis and GBS. 
Pregnant women will be sensitised during antenatal clinic 
about the study and then approached at admission to the labour 
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ward. All consenting women will be offered a rapid HIV and 
syphilis test in case they had not been tested in the current 
pregnancy. Women will be included if they are over the age of 
18 years and delivering at Kawempe hospital or if they are eman-
cipated minors aged between 14 and 17 years of age (live or 
stillbirth) and are willing to stay in the area for the first three 
months of life (or willing to travel to clinic until their child 
is 2 years old if their infant has known or presumed GBS 
infection).
For the Active surveillance cohort: all infants aged 0–90 days 
presenting to any of the paediatric units with signs and symptoms 
of sepsis will have a blood culture, lumbar puncture (if indi-
cated) and nasal swab collected prior to receipt of antibiotics. 
Caregivers of any infant with culture-confirmed GBS infection 
will be approached for consent to follow up infants until they 
are two years old to assess their neurodevelopmental outcomes.
See Figure 1 for the study flow diagram.
Figure 1. Participant Flow Diagram. GBS=Group B Streptococcus; iGBS=invasive GBS disease�
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Identification of participant for qualitative research 
(focus group discussions and key informant interviews)
-Community opinion leaders: These will be drawn from the 
communities surrounding Mulago/Kawempe hospitals and will 
include – religious leaders of the Protestant, Catholic and 
Muslim denominations, local political leaders of the villages 
(local council chairpersons and the secretary for women affairs 
of the respective executive committees) and one representative 
of the village health team, where available.
-Health service providers: Midwives who attend to pregnant 
women in the antenatal clinic and those that administer 
immunizations to pregnant women.
-Pregnant women: Pregnant women who have been immu-
nized during the current pregnancy will be approached for 
interview. They will be divided into the young (16 – 25 years) 
and the mature (>25 years) to avoid the mature women 
overshadowing the young ones during the discussions.
Study evaluations of birth cohort dyad
All birth cohort mother-infant pairs will undergo a limited 
newborn and maternal examination on the postnatal ward prior 
to discharge to examine the baby for any external congenital 
abnormalities and signs and symptoms of maternal or neonatal 
infection. The mother-infant pairs are followed up after 
discharge through telephone calls conducted by a health visitor 
at day 3 of life (+/- 2 days), day 30 of life (+/- 7 days) and 
day 90 of life (+/- 14 days). If the day three phone call is 
unsuccessful, then a second call will be made of day 7 of 
life (+/- 3 days). All phone calls will be attempted on three 
occasions at different times of day if the first call is unsuccess-
ful. Data recorded will include: the health status of mother and 
child; any medical care sought, any overnight hospital admis-
sions; any courses of intravenous or oral antibiotic therapy; the 
presence or absence of any signs of neonatal sepsis. In addi-
tion, any mother-infant pair attending for Expanded Programme 
on Immunization (EPI) visits at 6 and 10 weeks of age will be 
reviewed by study staff to establish health status and signs of 
infection.
During the three months of follow up any infant presenting 
with signs of sepsis will be examined by study staff and their 
clinical signs and investigations and any antibiotics administered 
will be recorded. Any infant with culture-confirmed GBS disease 
will be recruited into the neurodevelopmental follow up cohort. 
See Figure 2 and Figure 3 for details of follow up for both cohorts.
Sample collection of birth cohort dyad
All women will be approached for verbal informed consent 
(available as extended data19) at the time of admission in 
labour in order to collect a rectal swab, vaginal swab and cord 
blood at delivery. Full written informed consent will be obtained 
prior to discharge from hospital. If written consent is not 
obtained, samples will be destroyed.
Once full written informed consent (available as extended 
data19) is obtained a maternal serum sample will be collected for 
anti-GBS antibody level and routine blood screening in preg-
nancy (HIV status, syphilis and hepatitis B). Any positive results 
will be reported back to the clinical team so that appropriate 
treatment can be initiated.
Figure 2. Birth Cohort Follow Up. NPS=nasopharyngeal swab; LP=lumbar puncture; GBS=Group B Streptococcus; HINE= Hammersmith 
Infant Neurological Assessment; OFC=occipital frontal circumference; BSID=Bayley Scales of Infant development; PEDI=Paediatric Evaluation 
of disability instrument; EPI= extended programme on immunisations; iGBS= invasive GBS disease�
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Figure  3.  Neurodevelopmental  Follow  Up.  NPS=nasopharyngeal swab; LP=lumbar puncture; GBS=Group B Streptococcus; HINE= 
Hammersmith Infant Neurological Assessment; OFC=occipital frontal circumference; BSID=Bayley Scales of Infant development; 
PEDI=Paediatric Evaluation of disability instrument; EPI= extended programme on immunisations; iGBS= invasive GBS disease�
An assessment of the feasibility of performing minimally 
invasive tissue sampling on stillborn babies and rectal swabs from 
premature infants will be undertaken in order to finalise sample 
collection methodology for the main study.
Study evaluations active surveillance cohort
Any liveborn infant that develops signs of infection between 
birth and 3 months of age will have a blood culture and lumbar 
puncture taken (if clinically indicated) and a nasopharyngeal 
swab. All infants will be reviewed on admission and informa-
tion recorded on signs and symptoms, antimicrobial therapy 
and infant outcome (alive, died).
Any infant with culture-confirmed GBS disease will be recruited 
into the neurodevelopmental follow up cohort. A serum 
sample will be taken from mother and infant for cases of GBS 
disease, vagino-rectal swabs from the mother and rectal swab 
from the infant.
Study evaluations in survivors of GBS infection (birth or 
active surveillance cohort)
All infants with GBS disease will be followed-up until the 
age of two years. A trained psychologist will carry out the 
assessments. We will compare the neurodevelopment of infants 
with GBS with normal healthy controls with a ratio of 1 case 
to 1 control. Prechtl, Bayley Scales of Infant Development III 
(BSID-III) and HINE assessments will be performed during neu-
rodevelopmental follow-up if infants with GBS disease. See 
Table 2 and Figure 3.
Bayley Scales of Infant Development III (BSID-III) are used 
to assess neurodevelopment across five domains; receptive and 
expressive language, cognition, fine motor and gross motor 
according to standardised procedures. Bayley Scales have 
been validated in Uganda for use and provide a more detailed 
examination of neurodevelopmental domains than Ages and 
Stages (a screening tool). The HINE scores are video-recorded for 
quality control purposes. The recorded assessment are reviewed 
by another examiner to ensure consistency in the scoring20.
Focus group discussions, key informant and in-depth 
interviews
A series of focus group discussions, key informant and 
in-depth interviews will be conducted among service provid-
ers, program managers, community opinion leaders and preg-
nant women to explore ideas regarding sampling during labour, 
newborn sepsis and maternal immunization practices. Focus 
groups will contain 6-10 participants and will be conducted until 
saturation. Key informant interviews will be conducted with 
members of the focus group discussions to explore key themes 
identified. Focus Group Discussion guides are available as 
extended data19.
Laboratory evaluations
Rectal and vaginal swabs will be evaluated at MRC UVRI & 
LSHTM Research Unit, Entebbe, Uganda. Samples are sent 
to MRC with cold chain maintained at the end of each work-
ing day and plated on the same day. Maternal and infant 
swabs will be cultured in Todd Hewitt Broth and incubated 
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for 24hrs before being sub-cultured on Chromagar Strep B®. 
After 48hrs of incubation, presumptive GBS colonies will be 
identified by latex agglutination using StrepB® commercial kits 
and confirmed by rt-PCR and serotyped by gel-based PCR.
Rt-PCR: For rt-PCR primers as described in Diaz et al. 
(2010) will be used21 and a TaqMan® probe. Primers and 
probes are outlined in Table 3. PCR will be performed using a 
LightCycler (Roche). The following PCR components will 
be added to each well in duplicate: 0.5 mM primer, 0.2 mM 
probe, 2.0 mM MgCl2, 0.05 mM dH2O (2μl template in a final 
volume of 50 μl), 22.5μL Mastermix (Roche), 2.5mL sam-
ple DNA. A cycle threshold (Ct) value of 40 will be used as 
the cut-off for positive fluorescence detection signal of target 
Table 2. Neurodevelopmental assessments of infants with GBS disease.
Age at follow-up Neurodevelopment Child functioning Growth
3 months Prechtl & HINE Weight, Height, OFC
6 months BSID III & HINE PEDI Weight, Height, OFC
12 months BSID III & HINE PEDI Weight, Height, OFC
24 months BSID III & HINE 
HOME assessment 
Vision & hearing
PEDI Weight, Height, OFC
Legend - abbreviations: HINE= Hammersmith Infant Neurological Assessment; OFC=occipital frontal 
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amplification. Two positive controls and six negative controls 
will be included in all runs. Purified DNA from a known 
GBS strain will be used as positive control (in replicate) in 
a dilution corresponding to 107 bacterial genomes. As a negative 
control, sterile water will be added instead of DNA template 
into each of the six negative control wells. Each isolate 
will be tested in duplicate.
Gel-based PCR: For gel-based PCR for GBS serotyping, 
primers and components described by Imperi et al. (2010) 
will be used and primers are outlined in Table 3. PCR will 
be performed on a thermocycler. The PCR products will be 
subsequently visualised on a 1.5% agarose gel.
Pure GBS confirmed isolates will be stored on microbeads 
at -80˚C.
Blood and cerebrospinal fluid cultures will be evaluated at 
Makerere Microbiology Laboratories, Kampala from stillborn 
infants and blood cultures from infants with signs and symptoms 
of infection. All blood cultures are analysed within 
12 hours of collection. At least 1mL of blood will be 
collected in BACTEC bottles and incubated for 36 hours 
(10). Cell count, gram stain and culture will be performed on 
any cerebrospinal fluid. Any presumptive positive culture will 
be plated onto selective agar and identified by CAMP test. 
Any Pure GBS isolates will be stored on microbeads at -80˚C.
Cord and maternal/infant blood samples will be evaluated at 
MRC/UVRI at LSHTM Entebbe Uganda. The serum obtained 
will be analysed for antibody concentration using a standardized 
multiplex Luminex assay still under development and antibody 
function using an opsonophagocytic killing assay using stand-
ard reagents developed as part of the Bill and Melinda Gates 
funded assay standardization project (OPP1153630) to deter-
mine antibody concentrations for infants with and without 
invasive GBS disease. Maternal serum will be tested for HIV, 
syphilisand hepatitis B.
Primary outcomes
Maternal anti-GBS antibody concentration in infants with GBS 
disease compared to healthy controls.
Ability to recruit at least 50% of women delivering and collect 
samples
Acceptability of the study i.e. acceptability of sampling for 
live and stillbirths and infants with infections
Secondary outcomes
-    serotype-specific GBS colonisation rates during pregnancy 
in Kampala
-   neonatal GBS disease rates
-   GBS-related neurological impairment rates
-   GBS –associated stillbirth rates
-   all cause neonatal infection rates
Data entry, analysis and quality assurance
Detailed demographic data from pregnant woman and infant 
demographic information will be recorded and managed through 
the use of REDCap (Research Electronic Data Capture)23, a 
secure web-based electronic data collection platform. The 
REDCap server is hosted by Makerere University John’s 
Hopkins University, in Kampala. Audio recordings are used to 
collect all qualitative study data. These are then transcribed to 
Microsoft Word and analyzed using themes-based analysis.
Once captured, all quantitative data is subjected to cleaning 
and quality assurance processes before it is analysed. The 
PROGRESS GBS REDCap system has range, validation, and 
consistency checks to minimize data entry errors. Data reviews 
are undertaken at three stages, on day of collection by study 
coordinator, within one week by dedicated quality assurance 
technicians and weekly by the data manager to minimise any 
errors. Password protection for individual users is present 
on all electronic data entry systems.
Data collected includes:mode of delivery, antenatal risk factors 
for infection (Premature rupture of membranes/chorioamnionitis 
/maternal fever/raised white cell count), number of live births, 
information on maternal vaccination status, information of any 
infections leading up to delivery requiring antibiotics, time in 
hours of rupture of membranes prior to delivery, gestational age, 
birth weight, stillbirths/neonatal deaths/perinatal complications 
(birth asphyxia/meconium staining/signs of severe infection 
in the first three months of life (fever >38.5 degrees, raised 
white cell count, meningism). Gestational age calculated by 
ultrasonography if available; last normal menstrual period/ 
midwife palpation if ultrasound unavailable; Ballard score will 
also be performed on the newborn infants.
For any infants with suspected infection data is collected on 
maternal age, severity of infant illness (defined as need for 
hospital/intensive care stay), antimicrobial therapy and clinical 
outcome following disease (alive well, alive neurological 
impairment, death). For any infant with culture-confirmed GBS 
disease additional data is collected on pregnancy and birth as 
above. Data collection forms are available as extended data19.
Feasibility information
In order to determine the feasibility and acceptability of 
running a large sero-epidemiological study in this cohort, we will 
additionally collect information on enrollment rates, blood 
culture collection information (volume of blood culture, 
culture bottle weight, time of collection, time to BACTEC, time to 
positivity, time to Gram stain, time to final result, reporting of 
final result including antibiotic resistance, bacterial yield), ability 
to collect blood and CSF culture from infants with suspected 
sepsis and establish a denominator for infection rates (available 
as extended data19). In addition, we will assess the feasibility and 
acceptability of our sampling methods. Monthly vertical audits 
of data and samples are undertaken by the quality assurance team.
Graphpad Prism version 8 will be used for antibody analysis. 
Geometric mean and median antibody titres will be calculated 
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for cases and controls and comparisons made by t-test or 
Kruskall Wallis. reverse cumulative distribution curves and 
histogram plots will also be generated to compare antibody 
distribution between groups. Odds ratios for disease at differ-
ent thresholds will then be calculated. Finally, plots will be 
constructed to demonstrate the probability of infection at 
different thresholds based on the known disease incidence. We 
anticipate that the antibody concentration will not be normally 
distributed and so will log transform the data. If the data are 
then normally distributed, we will undertake comparison of 
the geometric mean antibody concentration and if the data 
remains non-normal we will use the Kruskall Wallis tests of 
medians to compare antibody concentrations between groups.
Rates for colonisation, disease, all-cause and GBS infection, 
death and stillbirth, enrollment and retention will be expressed 
as % or per 1000 pregnancies/livebirths as appropriate.
Ethical considerations
This study is conducted in accordance with the principles 
set forth in the ICH Harmonised Tripartite Guideline for Good 
Clinical Practice and the Declaration of Helsinki in its current 
version. The study has been approved by the Ugandan National 
Council for Science and Technology (UNCST; ref. HS 2496), 
Makerere University School of Medicine Research & Ethics 
Committee (SOMREC; 2018–130), and St George’s, Univer-
sity of London (SGUL REC ref 2020.0024) who sponsored the 
study.
Dissemination of information
Data will be reported using the STROBE_IN guidelines for cohort 
studies https://www.strobe-statement.org/index.php?id=available-
checklists, with the checklist deposited in OSF. Data will 
be disseminated through presentations to local and national 
bodies in Uganda and at international conferences. The final 
report will be prepared as a manuscript for publication.
Study status
The PROGRESS GBS study commenced on 24 April 2019. 
The study was paused on 26 March 2020 due to the corona-
virus pandemic and will restart on August 2020. The study 
successfully recruited 6000 participants between 24 April 2019 
and 26 March 2020 and took blood cultures from 5527 
infants with signs and symptoms of infection. The study is 
currently undertaking data cleaning in anticipation of the 
restart.
Discussion
This feasibility clinical observational and qualitative study will 
provide unique evidence about the feasibility of undertaking 
sero-epidemiological studies in Uganda. The clinical cohort study 
will provide evidence for GBS colonization, GBS disease and 
association with stillbirth for the first time in Uganda. The 
follow-up of infants with GBS infection will provide evidence 
on neurodevelopmental outcomes in this group in a low-
resource setting. Additionally, the study will provide evidence of 
pathogens and outcomes for 11,000 sepsis episodes in Uganda. 
Together, our results will contribute to global efforts to improve 
pregnancy, birth and neonatal infectious outcomes through 
maternal vaccination in Uganda. 
The study’s data collection is anticipated to be completed by 
October 2020 after which dissemination of the most important 
and relevant program learnings will begin at the end of 2020.
We directly developed the study design and conduct through 
engaging caregivers and programme facilitators (‘expert parents’). 
Through focus group discussions at a key-stakeholders meeting 
their priorities and were identified24 and these contributed to 
our research question and outcome measures’ development. 
Engaging the local community is key to the success of this 
and any future studies to improve maternal and infant health 
and we continue to work with participants and the wider 
community with results as they are available.
There are strong links between our programme and partner-
ship organisations working in Maternal and Child Health 
programming such as Kampala Capital City District Health 
Office and other collaborating institutions. In order to inform 
local and national health policies, we will disseminate research 
findings to the Ministry of Health. In a bid to contribute to 
the sustainability of the innovation at local and district levels, 
regional-level stakeholders, such as the District Health Office 
and heads of regional health and social services, will be engaged 
to support staff recruitment. In order to promote buy-in, 
facilitate fast-cycle learning, disseminate study findings and ulti-
mately promote sustainability of the programme, meetings for 
key stakeholders, such as local Non-Governmental Organisations 
working in maternal and child health will be held at least once 
during the project period.
Lessons learned from this feasibility study will be key to 
informing the ability of a low-resource country like Uganda to 
equitably take part on sero-epidemiological studies and provide 
much needed data on disease burden and potential mitigations, 
such as maternal vaccination. Ways to minimize loss to 
follow-up in these settings during this vulnerable period of 
time; maximizing blood culture positivity or maintaining 
sample integrity and tracking from large cohorts that are 
geographically distant are some of the lessons anticipated.
Data availability
Underlying data
No data are associated with this article.
Extended data
Open Science Framework: PROGRESS GBS. https://doi.org/ 
10.17605/OSF.IO/5A86F19
This project contains the following extended data: 
–    GBS Study Supplementary File 1_Denominator Data - 
Deliveries.docx
–    GBS Study Supplementary File 2_Denominator Data – 
Infant admissions.docx
–    GBS Study Supplementary File 3 - Data Collection Form.
pdf
–    GBS Study Supplementary File 4 - FGD guides.docx
–    GBS Study Supplementary File 5 - Parent Information 
Leaflets and Consent Forms.docx
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–    GBS Study Supplementary File 6 - Film.mp4
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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Interesting study addressing an important public health/child health problem globally and in 
particular in LMIC, proposing a large sample size efficacy study needed to develop a maternal GBS 
vaccine. The proposal is well developed and well written, and I have only a few 
questions/comments:
Informed consent: a rectovaginal swab will be obtained together with maternal delivery and 
cord sera. Women will be asked for verbal informed consent during labour, which is to be 
avoided. This issue is addressed by asking written informed consent prior to discharge 
which is difficult for the woken to refuse. 
As sensitization for the study takes place during antenatal care, one could envisage to 
collect the rectovaginal swabs during late trimester. 
 
1. 
HIV, syphilis and hepatitis samples have to be taken during pregnancy, not during labour.2. 
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: OBS/GYN
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
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Summary of planned study: 
The study addresses the burden of Group B Streptococcus (GBS) in neonates and the potential for 
maternal antibodies as a sero-correlate of protection. The aim is to evaluate the feasibility and 
acceptability of a GBS sero-epidemiology study, in Kampala, Uganda, a resource limited setting. 
Anti-GBS antibody titres will be assessed in infants with GBS infection compared to healthy 
controls. A mother and her infant will be recruited into the study at birth, and also any infant less 
than 3 years old with signs of infection will be recruited. Infants recruited at birth will be followed 
for 90 days. Any infant with confirmed GBS infection will be followed for two years during which a 
psychologist will assess neurodevelopment. Rectal and vaginal swabs will be collected from the 
mothers for GBS growth, and also cord blood at delivery. Blood culture will be done on blood from 
infants with suspected infection but also from stillbirths. A qualitative study employing focus 
group discussions, key informant and in-depth interviews will be nested in the project and the aim 
is to explore ideas regarding sampling during labour, newborn sepsis and maternal immunization 
practices. Secondary data such as ways to minimize loss to follow-up in a  resource limited setting; 
maximizing blood culture positivity or maintaining sample integrity and tracking from large 
cohorts that are geographically distant, will also be collected. 
 
My comments on the protocol:
In Figure 1, the Flow diagram, there is a typo error in Active surveillance box. 
 
○
Considering that HIV impacts on GBS maternal antibody levels (Le Doare et al., 20151), What 
happens when the mother is found HIV-infected? Do they proceed in the study? What is the 
analysis plan for HIV-infected mothers and or HIV-exposed infants? This study is located in 
an HIV endemic region and you might need to mention in your background the impact of 
HIV on maternal antibodies. 
 
○
Sample size calculation has been well considered and calculated. Should you also have 
considered the HIV rates? 
 
○
Your participant flow chart indicates recruitment from 14 years old. Why are you excluding 
mothers aged 14 to 15 years old in the focus group discussions? How about men (husbands 
or partners of pregnant women? (Merten et al., 20152). 
 
○
You have presented the sentences below taken from qPCR section as a study that has 
already taken place, and not a study protocol. Please correct to future tense. “…………. Two 
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known GBS strain was used as positive control in a dilution corresponding to 107 bacterial 
genomes. As a negative control, sterile water was added instead of DNA template. Each 
isolate was tested in duplicate……”. 
 
PCR section - You have specified one positive control of the mentioned two and one 
negative control of the six. What are the others? Or do you mean there will be 2 replicates of 
the positive control and six replicates of the negative control? 
 
○
The manuscript refers to components of mastermix as PCR conditions in the narrative (PCR 
section), but the cycling conditions have been rightly listed in Table 3. 
 
○
The PCR narrative refers to real-time PCR. Why is Table 3 providing cycling conditions for 
gel-based PCR? Also, the narrative has specified only one PCR target, CFB, but Table 3 has 
multiple other targets. Can you please clarify? 
 
○
Samples will be processed at MRC and Makerere. How far are these laboratories from the 
sample collection sites? You might consider including in your methods how the samples will 
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Author Response 03 Nov 2020
kirsty le doare, St George’s, University of London, London, UK 
Many thanks for your review of our protocol. We have taken note of your comments and 
amended the article as you suggest:
In Figure 1, the Flow diagram, there is a typo error in Active surveillance box. 
This is now corrected and a new version uploaded.
○
Considering that HIV impacts on GBS maternal antibody levels (Le Doare et al., 20151), 
What happens when the mother is found HIV-infected? Do they proceed in the study? What 
is the analysis plan for HIV-infected mothers and or HIV-exposed infants? This study is 
located in an HIV endemic region and you might need to mention in your background the 
impact of HIV on maternal antibodies. 
We are recruiting all mothers, whether living with HIV or not. We will analyse 
risk of GBS disease in this cohort separately. We have added some additional 
background to our introduction as you suggest.
○
Sample size calculation has been well considered and calculated. Should you also have 
considered the HIV rates? 
As this is a feasibility study, we will collect information on all women and then 
undertake a sensitivity analysis by HIV status.
○
Your participant flow chart indicates recruitment from 14 years old. Why are you excluding 
mothers aged 14 to 15 years old in the focus group discussions? How about men 
(husbands or partners of pregnant women? (Merten et al., 20152). 
The focus groups include pregnant women, men, community leaders and other 
key influencers. Because of cultural sensitivities, we have not included pregnant 
women <16 years.
○
You have presented the sentences below taken from qPCR section as a study that has 
already taken place, and not a study protocol. Please correct to future tense. “…………. Two 
positive controls and six negative controls were included in all runs. Purified DNA from a 
known GBS strain was used as positive control in a dilution corresponding to 107 bacterial 
genomes. As a negative control, sterile water was added instead of DNA template. Each 
isolate was tested in duplicate……”.
○
Thank you for noticing this error, we have now corrected to future tense.
PCR section – You have specified one positive control of the mentioned two and one 
negative control of the six. What are the others? Or do you mean there will be 2 replicates 
of the positive control and six replicates of the negative control?
○
As you correctly identify, we will have replicates of the positive and negative controls.
The manuscript refers to components of mastermix as PCR conditions in the narrative (PCR 
section), but the cycling conditions have been rightly listed in Table 3.
○
The mastermix referred to in the narrative is the platinum mastermix to which 
additional reagents are added. As such, we believe that the description is correct. We 
have changed the text to clarify this.
The PCR narrative refers to real-time PCR. Why is Table 3 providing cycling conditions for 
gel-based PCR? Also, the narrative has specified only one PCR target, CFB, but Table 3 has 
multiple other targets. Can you please clarify?
○
Thank you for pointing this out. The serotyping PCR is a gel-based PCR, this has now 
been clarified in the text. The cfb gene was used to identify GBS by rt-PCR but 
serotyping has multiple targets as you point out. We have clarified this in the text.
Gates Open Research
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Samples will be processed at MRC and Makerere. How far are these laboratories from the 
sample collection sites? You might consider including in your methods how the samples 
will be transferred and under what conditions, to maintain integrity.
○
The blood cultures will be taken to Makarere University for processing, this is 
approximately 4km from the trial site. We have spent a considerable amount of effort 
to ensure that sample integrity is maintained. Blood cultures arrive for culture within 
12 hours of collection. Swabs will be transferred to MRC daily with cold chain 
maintained and cultured on the same day. Centrifuged blood samples will be 
transferred daily to MRC and cultured will be aliquoted and frozen. We have added 
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